Alex Yang
Vermögen: 46 Mio $ am 31.08.2026
Vermögen: 46 Mio $ am 31.08.2026
Alex Yang is currently Chairman & Chief Executive Officer at Polaryx Therapeutics, Inc. since 2023, Chairman & Chief Executive Officer at Epygenix Therapeutics, Inc., and Chief Executive Officer at Mstone Partners Hong Kong Ltd. Formerly, Mr. Yang was Managing Partner at Kim & Chang.
Education includes undergraduate studies at State University of New York at Binghamton and graduate studies at New York University School of Law.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
POLARYX THERAPEUTICS, INC. 45,81 % | 27.07.2026 | 22 833 249 ( 45,81 % ) | 46 Mio $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| POLARYX THERAPEUTICS, INC. | Vorstandsvorsitzender | 01.03.2023 |
Epygenix Therapeutics, Inc.
Epygenix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for neurological disorders | Vorstandsvorsitzender | - |
Mstone Partners Hong Kong Ltd. | Vorstandsvorsitzender | - |
| Unternehmen | Position | Ende |
|---|---|---|
Kim & Chang
Kim & Chang Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 6 |
|---|---|
Kim & Chang
Kim & Chang Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
State University of New York at Binghamton
State University of New York at Binghamton Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New York University School of Law
New York University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mstone Partners Hong Kong Ltd. | |
Epygenix Therapeutics, Inc.
Epygenix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for neurological disorders | Health Technology |
Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biotechnology company that engages in discovery, development and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders | Commercial Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen